Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) on Tuesday shared data from cohort 4 of the Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis.In reaction to the positive data, Corvus Pharmaceuticals’ stock is trading higher with a session volume of 30.79 million compared to the average volume of 1.33 million.The cohort 4 data demonstrated favorable safety and efficacy results consistent with those from cohorts 1-3, including a deeper response in cohort 4 over the 8-week ...